New Zealand - English - Medsafe (Medicines Safety Authority)

carsl consulting - aripiprazole 30mg - tablet - 30 mg - active: aripiprazole 30mg excipient: hyprolose lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy. aripiprazole monotherapy is indicated for acute and maintenance treatment of manic and mixed episodes with bipolar i disorder with or without psychotic features. aripiprazole is indicated as an adjunctive therapy to either lithium or valporate for the acute treatment of manic and mixed episodes associated with bipolar i disorder with or without psychotic features.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 30 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; maize starch; magnesium stearate; hyprolose; colloidal anhydrous silica - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 30 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; microcrystalline cellulose; maize starch; magnesium stearate; hyprolose - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - aripiprazole, quantity: 30 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; iron oxide red; croscarmellose sodium; tartaric acid; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 30 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; tartaric acid; iron oxide red; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo sa-nv - aripiprazole 30 mg - tablet - 30 mg - aripiprazole 30 mg - aripiprazole

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - aripiprazole 30 mg - tablet - 30 mg - aripiprazole 30 mg - aripiprazole

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - aripiprazole 30 mg - tablet - 30 mg - aripiprazole 30 mg - aripiprazole

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - aripiprazole 30 mg - tablet - 30 mg - aripiprazole 30 mg - aripiprazole

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 20 mg - tablet, uncoated - excipient ingredients: tartaric acid; croscarmellose sodium; microcrystalline cellulose; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.